BioCryst: Estimate-Beating Q1 But Risks Are Considerable (NASDAQ:BCRX)


Share post:


This is my second BioCryst (NASDAQ:BCRX) article, following 04/11/2022’s “BioCryst: After The Fall” (“FALL“). The downdraft referenced in the title to FALL was caused by its decision to pause enrollment in phase 2 trials


Please enter your comment!
Please enter your name here

Related articles

My Employee Quit Over a Misdirected Email

... and two other tricky workplace dilemmas.

How to Move a WordPress Site to New Hosting

WordPress migration or moving WordPress to a new host doesn't need to be overwhelming. When you simplify the...

Keep Business Private with a Second Phone Number for $20

Disclosure: Our goal is to feature products...